Her2 Targeted Therapy | List of Frontiers open access articles

Case Report

Published on 10 Nov 2025

HER2-targeted therapy combined with multidisciplinary management in advanced gallbladder cancer: a case report with 90-month survival

in Cancer Molecular Targets and Therapeutics

Yulin Wang
Guangwei Tian
Yu Cheng
Shuang Wu
Yanfang Wei
Shize Fan
Jinglei Qu
Jin Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1669818

1,497 views

Original Research

Published on 03 Apr 2023

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Yanjie Han
Yuanyuan Xiong
Tao Lu
Rongrong Chen
Yuan Liu
Hui Tang
Ruixuan Geng
Yingyi Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1121708

6,351 views
6 citations

Review

Published on 13 Mar 2025

HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy

in Cancer Immunity and Immunotherapy

Qiangzu Shao
Junge Deng
Haoran Wu
Zeping Huang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1560280

8,331 views
10 citations

Original Research

Published on 03 Feb 2022

The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy

in Head and Neck Cancer

Natsuki Saigusa
Hideaki Hirai
Yuichiro Tada
Daisuke Kawakita
Masato Nakaguro
Kiyoaki Tsukahara
Satoshi Kano
Hiroyuki Ozawa
Takahito Kondo
Kenji Okami

Frontiers in Oncology

doi 10.3389/fonc.2021.779882

8,601 views
19 citations

Case Report

Published on 19 Jan 2023

HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review

in Breast Cancer

Min-long Chen
Wenjie Yu
Binbin Cui
Yijian Yu
Zhaosheng Ma

Frontiers in Oncology

doi 10.3389/fonc.2022.980635

3,645 views
2 citations

Case Report

Published on 06 Jan 2022

Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient

in Cancer Immunity and Immunotherapy

Li Wang
Xiaomo Li
Yurong Cheng
Jing Yang
Si Liu
Tonghui Ma
Li Luo
Yanping Hu
Yi Cai
Dong Yan

Frontiers in Immunology

doi 10.3389/fimmu.2021.784861

7,250 views
12 citations

Original Research

Published on 07 Nov 2025

Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy

in Cancer Immunity and Immunotherapy

Xinlin Liu
Wanpeng Yu
Yihuan Wang
Dongming Xing
Haiming Huang
Wenjing Zhu
Peng Sun

Frontiers in Immunology

doi 10.3389/fimmu.2025.1711433

1,899 views

Review

Published on 27 Feb 2026

Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer: from mechanistic exploration to clinical translation

in T Cell Biology

Yongxi Wang
Zhe Zhang
Zhuo Chen
Xiaoyun Xie
Fang Wang

Frontiers in Immunology

doi 10.3389/fimmu.2026.1741333

196 views

Case Report

Accepted on 25 Feb 2026

Pathological Complete Response to Neoadjuvant TACHP in HER2-Positive/HR-Positive Inflammatory Breast Cancer: A Case Report

in Breast Cancer

Mengjie Guo
Guangjin Liu
Xin Han
Rui Jiao
Jinmao Li

Frontiers in Oncology

Case Report

Published on 17 Jun 2024

Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review

in Breast Cancer

Yanfang Lan
Jiahui Zhao
Fangrui Zhao
Juanjuan Li
Xiangpan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1338661

4,903 views
1 citation

Review

Published on 22 Apr 2020

Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

in Women's Cancer

María Florencia Mercogliano
Sofía Bruni
Patricia V. Elizalde
Roxana Schillaci

Frontiers in Oncology

doi 10.3389/fonc.2020.00584

35,585 views
166 citations

Original Research

Published on 04 Jun 2021

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

in Breast Cancer

Soong June Bae
Jee Hung Kim
Sung Gwe Ahn
Hei-Cheul Jeung
Joohyuk Sohn
Gun Min Kim
Min Hwan Kim
Seung Il Kim
Seho Park
Hyung Seok Park

Frontiers in Oncology

doi 10.3389/fonc.2021.689587

10,698 views
20 citations

Original Research

Published on 21 Jan 2022

CuS@BSA-NB2 Nanoparticles for HER2-Targeted Photothermal Therapy

in Pharmacology of Anti-Cancer Drugs

Ming Ying
Qin Li
Jingbo Wu
Yihang Jiang
Zhourui Xu
Mingze Ma
Gaixia Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2021.779591

6,666 views
18 citations

Case Report

Published on 25 Apr 2025

Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights

in Pharmacology of Anti-Cancer Drugs

Guanbin Huang
Tongtong Xia
Dongxiao Yang
Muwen Lin
Yiping Luo
Yuchan Li
Hualin Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564834

3,942 views
2 citations

Original Research

Published on 06 Oct 2022

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors

in Cancer Molecular Targets and Therapeutics

Yin Guan
Yutong Wang
Hongxia Li
Jing Meng
Xia You
Xiaofeng Zhu
Qin Zhang
Tingting Sun
Chuang Qi
Guangyu An

Frontiers in Oncology

doi 10.3389/fonc.2022.986674

8,400 views
9 citations

Original Research

Published on 19 Nov 2024

Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study

in Cancer Immunity and Immunotherapy

Xiaobin Chen
Qindong Cai
Lin Deng
Minyan Chen
Min Xu
Lili Chen
Yuxiang Lin
Yan Li
Yali Wang
Hanxi Chen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1465862

3,695 views
6 citations

Articles

HER2-targeted therapy combined with multidisciplinary management in advanced gallbladder cancer: a case report with 90-month survival

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy

The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy

HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review

Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient

Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy

Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer: from mechanistic exploration to clinical translation

Pathological Complete Response to Neoadjuvant TACHP in HER2-Positive/HR-Positive Inflammatory Breast Cancer: A Case Report

Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review

Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

CuS@BSA-NB2 Nanoparticles for HER2-Targeted Photothermal Therapy

Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors

Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study